Cargando…
Use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids
Ketamine is a standard anaesthetic drug that has been studied as a possible treatment for acute suicidal ideation. Aside to the potential psychotropic effects of ketamine, a Cochrane review reported that available studies suggest a modest effect of ketamine for chronic pain months to years after sur...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747796/ https://www.ncbi.nlm.nih.gov/pubmed/29133582 http://dx.doi.org/10.1136/bcr-2017-222059 |
_version_ | 1783289317211242496 |
---|---|
author | Bigman, Daniel Kunaparaju, Sindhura Bobrin, Bradford |
author_facet | Bigman, Daniel Kunaparaju, Sindhura Bobrin, Bradford |
author_sort | Bigman, Daniel |
collection | PubMed |
description | Ketamine is a standard anaesthetic drug that has been studied as a possible treatment for acute suicidal ideation. Aside to the potential psychotropic effects of ketamine, a Cochrane review reported that available studies suggest a modest effect of ketamine for chronic pain months to years after surgical intervention. We present a patient with acute suicidal ideation who required immediate inpatient psychiatric admission in the setting of concurrent chronic pain on cannabinoids which could not be prescribed within our inpatient hospital setting. This presented a clinical dilemma to rapidly reverse the patient’s suicidality while substituting the patient’s prescribed cannabinoid products with an alternative pain regimen. Since there is emerging support in the use of ketamine in suicidality and chronic pain, we administered ketamine while withholding cannabinoid products and found evidence to support its use in rapid reversal of suicidal ideation and temporary chronic pain relief. |
format | Online Article Text |
id | pubmed-5747796 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-57477962018-01-03 Use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids Bigman, Daniel Kunaparaju, Sindhura Bobrin, Bradford BMJ Case Rep Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation) Ketamine is a standard anaesthetic drug that has been studied as a possible treatment for acute suicidal ideation. Aside to the potential psychotropic effects of ketamine, a Cochrane review reported that available studies suggest a modest effect of ketamine for chronic pain months to years after surgical intervention. We present a patient with acute suicidal ideation who required immediate inpatient psychiatric admission in the setting of concurrent chronic pain on cannabinoids which could not be prescribed within our inpatient hospital setting. This presented a clinical dilemma to rapidly reverse the patient’s suicidality while substituting the patient’s prescribed cannabinoid products with an alternative pain regimen. Since there is emerging support in the use of ketamine in suicidality and chronic pain, we administered ketamine while withholding cannabinoid products and found evidence to support its use in rapid reversal of suicidal ideation and temporary chronic pain relief. BMJ Publishing Group 2017-11-12 /pmc/articles/PMC5747796/ /pubmed/29133582 http://dx.doi.org/10.1136/bcr-2017-222059 Text en © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation) Bigman, Daniel Kunaparaju, Sindhura Bobrin, Bradford Use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids |
title | Use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids |
title_full | Use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids |
title_fullStr | Use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids |
title_full_unstemmed | Use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids |
title_short | Use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids |
title_sort | use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids |
topic | Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747796/ https://www.ncbi.nlm.nih.gov/pubmed/29133582 http://dx.doi.org/10.1136/bcr-2017-222059 |
work_keys_str_mv | AT bigmandaniel useofketamineforacutesuicidalideationinapatientwithchronicpainonprescribedcannabinoids AT kunaparajusindhura useofketamineforacutesuicidalideationinapatientwithchronicpainonprescribedcannabinoids AT bobrinbradford useofketamineforacutesuicidalideationinapatientwithchronicpainonprescribedcannabinoids |